Publication at First Faculty of Medicine |
2015
Abstract
Tocilizumab is a monoclonal antibody targeting interleukin-6 receptors approved for the treatment of rheumatoid arthritis. It is available as both intravenous infusions and subcutaneous injections, and the efficacy and safety of both application forms are comparable.
Patients unable to receive methotrexate for various reasons may receive tocilizumab as monotherapy. Published data from clinical trials, biological therapy registries and analysis of post-marketing pharmacovigilance database confirm good long-term efficacy and safety of therapy with tocilizumab.